Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection
Clinical trial NCT07149454 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT07149454
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-18
- Primary completion
- 2026-05-27
- Enrollment
- 68
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.